Table 1.

Baseline characteristics of the randomized population.

Demographic variable	Vildagliptin 50 mg bid N = 188	Voglibose 0.2 mg tid N = 192
Age (years)*	60.3 (±10.48)	58.0 (±9.32)
Age category ≥65 years†	68 (36.2%)	52 (27.1%)
Gender†
Male	121 (64.4%)	130 (67.7%)
Female	67 (35.6%)	62 (32.3%)
Body weight*	64.4 (±10.8)	66.5 (±10.3)
BMI (kg/m2)*	24.8 (±3.05)	25.0 (±3.35)
HbA1c (%)*	7.5 (±0.9)	7.6 (±0.9)
FPG (mmol/l)*	8.9 (±1.7)[160.4(±30.1)]$	9.1 (±1.9)[164(±33.5)]$
1-h PPG (mmol/l)*	15.2 (±2.2)[272.8(±40.1)]$	15.0(±2.4)[270(±43.3)]$
2-h PPG (mmol/l)*,‡	13.6 (±3.0)[244.9(±53.2)]$	13.5(±3.0)[243.8(±54.2)]$
Duration of T2D (years)*	5.1 (±5.1)	5.6 (±5.0)

BMI, body mass index; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; PPG, postprandial glucose; T2D, type 2 diabetes.

^*Mean (±s.d.).

^†n (%).

^‡N = 187 for vildagliptin 50 mg bid group.

^$mg/dl.